First Patient Dosed in Clinical Study of TLX250-CDx in Bladder Cancer
Telix announces that a first patient has been dosed in a Phase I study of TLX250-CDx in patients with bladder…
Read moreNews & Views
IPAX-1 (TLX101 for Glioblastoma Therapy) Clinical Trial Update
Telix announces preliminary safety data from the IPAX-1 Ph I/II study, with a follow-on study being planned in front-line…
Read more
Telix Update on FDA New Drug Application Review for Illuccix®
Telix announces participation in a late-cycle meeting with the U.S. FDA regarding the ongoing review of the NDA for its prostate cancer imaging investigational product…
Read more
Telix Pharmaceuticals and Applied Radiology launch TelixU Medical Education Platform Focused on Radiopharmaceutical Research
Telix is pleased to announce the launch of TelixU, a new educational platform focused on radiopharmaceutical research in partnership with leading medical imaging journal, Applied…
Read more
Scott Law joins Telix as SVP Global Manufacturing Operations
News,
Telix is delighted to announce that Scott Law has joined the Company as Senior Vice President, Global Manufacturing…
Read more
Telix and ATS Awarded $1.56M ‘Eurostars’ Grant for Alpha Therapy
Advanced Nuclear Medicine Ingredients S.A, a wholly owned European subsidiary of Telix, and Alpha Therapy Solutions announce €990K (A$1.56M) ‘Eurostars-2’ research grant from the EUREKA…
Read more
Telix Symposium at SNMMI 2021 Virtual Annual Meeting
Telix is pleased to announce we will be presenting at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2021 Virtual Annual Meeting to be held 11 – 15…
Read more
Telix and Eckert & Ziegler Sign US Co-Promotion Agreement for Prostate Cancer Imaging
Telix announces co-promotion agreement with EZAG for Telix’s investigational prostate cancer imaging product Illuccix® and EZAG’s GalliaPharm® gallium-68…
Read more
Telix to Present at the 2021 Jefferies Virtual Healthcare Conference
Telix is pleased to announce that Chief Executive Officer, Dr. Christian Behrenbruch, will present at the Jefferies Virtual Healthcare Conference…
Read more